Your Health, We Care
Release date: 2024-08-09 10:54:47 Recommended: 136
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation. Exkivity reduces the growth of non-small cell lung cancer by binding to and inhibiting EGFR exon 20 insertion mutations.
EXKIVITY can cause ILD/pneumonitis, which can be fatal. In the pooled EXKIVITY safety population, ILD/pneumonitis occurred in 4.3% of patients including 0.8% Grade 3 events and 1.2% fatal events.
Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Immediately withhold EXKIVITY in patients with suspected ILD/pneumonitis and permanently discontinue EXKIVITY if ILD/pneumonitis is confirmed.
Interstitial lung disease (ILD)/pneumonia caused by Exkivity (moboxinib) is a potential adverse drug reaction, and its clinical manifestations mainly include the following aspects:
The most common symptom of ILD/pneumonia is dyspnea, and patients may feel strained breathing and need to breathe more frequently to maintain a normal oxygen supply.
Patients may have a dry cough or a cough with sputum, which may be continuous or intermittent.
Some patients may have a fever at the time of ILD/pneumonia, which is a common manifestation of the body's response to inflammation.
Because ILD/pneumonia can be fatal, patients should be closely monitored for pulmonary symptoms during the use of Exkivity. Symptoms of suspected ILD/pneumonia should be evaluated and diagnosed immediately.
If ILD/pneumonia is confirmed, Exkivity should be discontinued immediately and treated accordingly depending on the severity of the condition. Treatment may include drugs such as glucocorticoids and immunosuppressants, as well as supportive care such as oxygen therapy and mechanical ventilation.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
